

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Statement of Audited Standalone Financial Results for the Quarter and Year Ended on 31/03/2018

Rs. In Lacs other than EPS

						N3. III Lu	Rs. In Lacs other than EPS	
Sr. No.		Particulars	(Quarter Ended		Year Ended		
			31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017	
		4	Audited	Unaudited	Audited	Audited	Audited	
1	5	Revenue from Operations	3005.82	3087.44	2740.05	11467.42	10330.60	
2		Other Income	64.81	69.23	88.78	339.40	295.52	
3		Total income	3070.63	3156.67	2828.83	11806.82	10626.12	
4		Expenses						
	(a)	Cost of Materials Consumed	336.95	257.14	254.63	986.21	804.25	
	(b)	Purchase of Stock-in-trade	757.88	621.17	654.16	2064.62	2447.12	
	(c)	Changes in inventories of Finished Goods, Stock-in-					*	
	(0)	trade and WIP	53.38	-87.39	-174.68	348.29	-195.45	
	(d)	Employee benefit expenses	740.06	680.24	605.44	2769.18	2520.99	
	(e)	Finance Costs	12.64	11.10	12.62	41.21	40.99	
	, ,	Depreciation and Amortisation Expense	38.21	37.63	44.82	150.02	178.72	
	(g)	other expenses	266.96	970.43	831.71	2920.40	2781.61	
		Total Expenses	2206.08	2490.32	2228.70	9279.93	8578.23	
5		Profit before exceptional items & Tax	864.55	666.35	600.13	2526.89	2047.89	
6		Exceptional Items	0.00	0.00	0.00	0.00	0.00	
7		Profit before tax	864.55	666.35	600.13	2526.89	2047.89	
8		Tax Expense						
	(i)	Current Tax	315.00	215.00	250.41	830.00	710.00	
	(ii)	Income Tax for previous years	14.24	0.00	0.00	14.24	0.00	
		Deferred Tax	-22.47	-2.73	-3.67	-38.57	-12.87	
9		Profit after tax for the period	557.78	454.08	353.39	1721.22	1350.76	
10		Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	464.93	464.93	458.94	464.93	
11		Other Comprehensive Income						
	(i)	Items that will not be reclassified to profit or loss	-125.57	6.87	0.00	-97.99	0.00	
	(::)	Income Tax relatiing to Items that will not be						
	(ii)	reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
	(iii)	Items that will be reclassified to profit or loss	27.60	0.00	21.10	27.60	21.10	
	(:, .) [Income Tax relatiing to Items that will be reclassified			1			
	(iv)	to profit or loss	-0.03	0.00	0.00	-0.03	0.00	
12		Total Comprehensive Income for the period	459.78	460.95	374.49	1650.80	1371.86	
13		Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	12.15	9.77	7.60	37.50	29.05	

Notes:

- 1 The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder from 1st April, 2017 and accordingly, these standalone audited financial results (including figures for the previous quarter and year ended 31st March, 2017) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS.
- 2 The Board of Directors has recommended a final dividend of Rs. 6/- (60%) per equity share of Rs.10/- each of the Company for the financial year 2017-18.
- The above statement of Audited standalone Financial results were reviewed and recommended by the Audit Committee and approved by the Soard of Directors at their respective meeting held on 29th May, 2018.



Science hai toh Hope hai * Hope hai toh Health hai * Health hai toh Happiness hai *



Email: info@jenburkt.com

www.jenburkt.com

CIN No. L24230MH1985PLC036541





Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

- The EPS calculated above is based on the paidup equity share capital of the Company, for the relevant quarter/year.
- The Company had bought back 59922 equity shares during the year, resultantly the current paid up equity share stands at 4589378 equity 5 shares of Rs.10/- each.
- The figures for the quarter ended 31st March, 2018 are the balancing figures between Audited Figures for the year ended on 31st March 2018 and publised year to date figures upto the third quarter ended 31st December, 2017.
- Reconciliation of net profit for the quarter and year ended on 31st March 2017 as stated under previous GAAP and IND AS is as under:

Particulars	Profit Reconciliation for the quarter ended on 31/03/2017	Profit Reconciliation for the year ended on 31/03/2017
Net Profit for the quarter as per Previous GAAP	353.39	1346.45
ADD/(LESS) : Adjustments of difference between figures as per GAAP and IND AS		
Deferment of Revenue Recognition	0.47	1.90
Restatement of Loss on Sale of Investment to OCI	4.42	4.42
Impact of Deferred Tax	-0.02	0.05
Discounting of Rent Deposit	-0.51	-2.06
Income Tax of Previous Years	-2.90	0.00
Net Profit for the period as per IND AS	354.85	1350.76

Reconciliation of equity for the year ended on 31st March 2017 as stated under previous GAAP and IND AS is as under

Particulars	Equity Reconciliation as on 31/03/2017
Total Equity as per previous GAAP	5365.32
ADD/(LESS) : Adjustments of difference between figures as per GAAP and IND AS	0.00
Adjustment due to valuation of Investment at market value through OCI	74.04
Deferment of Revenue Recognition	1.90
Restatement of Loss on Sale of Investment to OCI	4.42
Impact of Deferred Tax	0.05
Discounting of Rent Deposit	-2.06
Net Equity as per INDAS	5443.67

- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures of the previous year/period have been regrouped/recast/rearranged to render them comparable with figures of the current period.

Science hai toh Hope hai 🎇 Hope hai toh Health hai 🎆 Health hai toh Happiness hai 💥



Email: info@jenburkt.com

www.jenburkt.com





Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

			Standalone Statemen	t of Assets and Lia	abilities	
	-					(Rs.in Lacs)
Sr. No.			Particulars		AS AT 31/03/2018	AS AT 31/03/2017
					(Audited)	(Audited)
(A)			ASSETS			
(1)	/-\		Non Current Assets		044.01	1040.01
	(a)		Property, Plants & Equipments		944.91	1049.81
	(b)		Goodwill		0.14 11.78	0.14 12.69
	(c)		Other Intangible assets Financial Assets		11./8	12.69
	(d)	/:\	Investments		162.82	138.64
		(i) (ii)	Loans		102.82	
					0.00	25.72
	(e)	(111)	Others		25.03	24.78
(2)	(e)		Other non-current assets	120	25.05	24.70
(2)	(-)		Current Assets Inventories		680.44	1074.56
	(a) (b)		Financial Assets		000.44	1074.56
	(D)	(i)	Investments		378.78	55.06
		(ii)	Trade receivables		1253.78	907.18
			Cash and cash euivalents		118.37	198.66
			Bank balance other than (iii)		3992.98	4009.21
			Loans		28.85	45.57
			Others		53.41	24.99
	(c)	(VI)	Other current assets		85.56	73.35
	(0)		Other current assets		65.50	75.55
				Total Assets	7747.14	7640.38
(B)			EQUITY AND LIABILITIES	1		
(1)			Equity			
	(a)		Equity Share capital		458.94	464.93
	(b)		Other Equity - Reserves & Surplus		5667.09	4978.75
(2)			Non Current Liabilities			
	(a)		Financial Liabilities - Borrowings		23.59	24.13
	(b)		Deferred tax liabilities (Net)		11.79	50.27
7-1	(c)		Other non-current liabilities		278.79	292.74
(3)			Current Liabilities			
	(a)	***	Financial Liabilities		0.50	642.26
		(i)	Borrowings		0.53	613.36
		(ii)	Trade payables		412.21	601.62
	71.3	(iii)	Other financial liabilities		677.77	465.89
	(b)		Other current liabilities		189.18	78.67
	(c)		Provisions (No. 1)		18.62	34.39
	(d)		Current tax liabilities (Net)		8.62	35.64

By order of the Board

For Jenburkt Pharmaceuticals Ltd.

7747.14

7640.38

Place : Mumbai

Date : 29" May, 2018

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

long



Total Equity and Liabilities

